Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bioanalytical Systems stock | $8.53

Own Bioanalytical Systems stock in just a few minutes.

Fact checked

Bioanalytical Systems, Inc is a diagnostics & research business based in the US. Bioanalytical Systems shares (BASI) are listed on the NASDAQ and all prices are listed in US Dollars. Bioanalytical Systems employs 397 staff and has a trailing 12-month revenue of around USD$60.5 million.

How to buy shares in Bioanalytical Systems

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Bioanalytical Systems. Find the stock by name or ticker symbol: BASI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bioanalytical Systems reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$8.53, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Bioanalytical Systems, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Bioanalytical Systems. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Bioanalytical Systems share price

Use our graph to track the performance of BASI stocks over time.

Bioanalytical Systems shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$8.53
52-week rangeUSD$3.05 - USD$10.74
50-day moving average USD$7.0845
200-day moving average USD$5.5319
Wall St. target priceUSD$17
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.124

Buy Bioanalytical Systems shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bioanalytical Systems stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bioanalytical Systems price performance over time

Historical closes compared with the close of $8.53 from 2020-12-18

1 week (2021-01-08) -34.23%
1 month (2020-12-16) 7.03%
3 months (2020-10-15) 66.60%
6 months (2020-07-15) 81.49%
1 year (2020-01-15) 56.51%
2 years (2019-01-15) 556.15%
3 years (2018-01-12) 255.42%
5 years (2016-01-15) 527.21%

Is Bioanalytical Systems under- or over-valued?

Valuing Bioanalytical Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioanalytical Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bioanalytical Systems's EBITDA

Bioanalytical Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.2 million.

The EBITDA is a measure of a Bioanalytical Systems's overall financial performance and is widely used to measure a its profitability.

Bioanalytical Systems financials

Revenue TTM USD$60.5 million
Gross profit TTM USD$18.2 million
Return on assets TTM -2.25%
Return on equity TTM -51.19%
Profit margin -7.75%
Book value $0.69
Market capitalisation USD$105.7 million

TTM: trailing 12 months

Shorting Bioanalytical Systems shares

There are currently 10,597 Bioanalytical Systems shares held short by investors – that's known as Bioanalytical Systems's "short interest". This figure is 117.7% up from 4,868 last month.

There are a few different ways that this level of interest in shorting Bioanalytical Systems shares can be evaluated.

Bioanalytical Systems's "short interest ratio" (SIR)

Bioanalytical Systems's "short interest ratio" (SIR) is the quantity of Bioanalytical Systems shares currently shorted divided by the average quantity of Bioanalytical Systems shares traded daily (recently around 36541.379310345). Bioanalytical Systems's SIR currently stands at 0.29. In other words for every 100,000 Bioanalytical Systems shares traded daily on the market, roughly 290 shares are currently held short.

However Bioanalytical Systems's short interest can also be evaluated against the total number of Bioanalytical Systems shares, or, against the total number of tradable Bioanalytical Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bioanalytical Systems's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Bioanalytical Systems shares in existence, roughly 0 shares are currently held short) or 0.0015% of the tradable shares (for every 100,000 tradable Bioanalytical Systems shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bioanalytical Systems.

Find out more about how you can short Bioanalytical Systems stock.

Bioanalytical Systems share dividends

We're not expecting Bioanalytical Systems to pay a dividend over the next 12 months.

Bioanalytical Systems share price volatility

Over the last 12 months, Bioanalytical Systems's shares have ranged in value from as little as $3.05 up to $10.74. A popular way to gauge a stock's volatility is its "beta".

BASI.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bioanalytical Systems's is 1.7638. This would suggest that Bioanalytical Systems's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bioanalytical Systems overview

Bioanalytical Systems, Inc., doing business as Inotiv, a pharmaceutical development company, provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical toxicology and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site